Citigroup Global Markets Asia Limited, on behalf of an offeror, has made voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd., excluding those already owned or agreed to be acquired by the offeror and its concert parties, and to cancel all outstanding share options. WuXi Biologics, as the controlling shareholder of the offeror, has provided written approval for the transaction. A circular with further details and recommendations from the directors of the offeror is expected to be distributed to shareholders on or before 4 February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260114-11991246), on January 14, 2026, and is solely responsible for the information contained therein.